Due to the special nature of medicines, returns and exchanges are not supported.

Final delivery from the nearest overseas warehous NEW

Compare

Action	Delete
Image
Title	Glofitamab Injection.
Price
Button	阅读更多
Excerpt	How effective is glofitamab in treatment? Glofitamab (glofitamab-gxbm) is a bispecific antibody that can simultaneously target CD3 and CD20, activating T cells to release cancer cell-killing proteins. Clinical trials have shown that it has significant efficacy in treating relapsed or refractory diffuse large B-cell lymphoma, with a complete remission rate of 40% and an objective remission rate of 52%. The drug performed well in clinical trials, with significant efficacy and high safety, greatly improving the quality of life of patients. Diffuse large B-cell lymphoma and follicular lymphoma are common malignant tumors that have a serious impact on the lives of patients. In recent years, glofitamab (glofitamab-gxbm), as a new monoclonal antibody drug, has shown good efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma and large B-cell lymphoma caused by follicular lymphoma. This article will specifically discuss the therapeutic efficacy of glofitamab. 1. The therapeutic mechanism of Gefituzumab Gefituzumab is a bispecific antibody that achieves targeted killing of cancer cells by binding to two proteins, CD20 and CD3. CD20 is a leukocyte antigen widely expressed on the surface of B-cell malignant tumor cells, while CD3 is a membrane protein on the T-cell receptor that participates in cellular immune responses. When Gefituzumab binds to CD20 and CD3, they activate T cells and cause them to attack and kill cancer cells. This new immunotherapy can effectively promote the clearance of tumor cells by the immune system. 2. Clinical trial results of Gefituzumab Recent studies have shown that Gefituzumab has shown significant efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma and large B-cell lymphoma caused by follicular lymphoma. Clinical trial data show that the drug has produced a high overall response rate and complete remission rate in patients with these malignant tumors. After receiving Gefituzumab treatment, many patients have significantly reduced tumor size, relieved symptoms, and prolonged survival. 3. Advantages and safety of Gefituzumab Compared with traditional chemotherapy and other immunotherapies, Gefituzumab has unique advantages. First, due to its specific binding mechanism, Gefituzumab can more accurately identify malignant tumor cells and reduce damage to normal cells, thereby reducing adverse reactions during treatment. Secondly, Gefituzumab uses bispecific antibody technology, which can more effectively activate T cells and enhance immune killing effects. In addition, the medication regimen of Gefituzumab is also more convenient, allowing patients to have a more effective and comfortable treatment experience. Regarding the safety of Gefituzumab, current clinical data show that it is well tolerated in most patients. Common adverse reactions include fever, respiratory tract infection, fatigue, etc., but most reactions are mild or moderate and can be alleviated by appropriate supportive treatment. In clinical use, patients' drug reactions and adverse events still need to be closely monitored to ensure the safety and effectiveness of treatment. 4. Further research and application prospects of Gefituzumab Although Gefituzumab has shown potential in the treatment of large B-cell lymphoma, its therapeutic effect in different types of malignant tumors and other diseases still needs further research and verification. With the development of science and technology and a deeper understanding of tumor biology, we can expect Gefituzumab and its similar drugs to play a wider role in tumor treatment in the future. As a new type of immunotherapy drug, Gefituzumab has shown good efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma and large B-cell lymphoma caused by follicular lymphoma. Its targeted effect and good tolerability make it a promising treatment option, providing patients with new survival opportunities and the possibility of improving their quality of life. With further research, we can expect more applications of Gefituzumab in tumor treatment.
Stock status	In stock
Brand	injection
Select all

Apply

Compare more products

More